Becker's Healthcare January 4, 2024
The FDA is looking into whether hair loss, aspiration and suicidal thoughts may be side effects of GLP-1 receptor agonists, a popular class of weight-loss drugs.
The agency on Jan. 2 published a summary of reports received through its Adverse Event Reporting System, or FAERS, saying it is “evaluating the need for regulatory action” after receiving reports of alopecia, aspiration and suicidal thoughts in people using medications such as Ozempic and Wegovy. The reports are based on data collected from July through September.
The FDA’s site notes that the appearance of a drug on the list “means that the FDA has identified a potential safety issue, but it does not mean that the FDA has identified a causal relationship...
Today's Sponsors
Today's Sponsor